First Patient Treated With Benitec Biopharma’s Oculopharyngeal Muscular Dystrophy Gene Therapy Shows Swallowing ...
The first patient treated in Benitec Biopharma’s phase 1b/2a clinical trial (NCT06185673) evaluating BB-301, its investigational adeno-associated virus (AAV) vector-based silence and replace gene therapy for the treatment of oculopharyngeal muscular …